Medicinova (MNOV) Liabilities and Shareholders Equity (2010 - 2026)

Medicinova (MNOV) has reported Liabilities and Shareholders Equity for 16 consecutive years, with $45.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 18.39% year-over-year to $45.6 million; the TTM figure through Dec 2025 stood at $195.4 million (down 17.64% YoY), while the FY2025 annual figure was $45.6 million, down 18.39% from the prior year.
• Liabilities and Shareholders Equity slipped to $45.6 million in Q4 2025 per MNOV's latest filing, from $47.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $96.1 million in Q1 2021 and bottomed at $45.6 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $69.7 million across 5 years, with a median of $68.4 million in 2023.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity gained 24.78% — and 2025, when it slipped 18.39%.
• Medicinova's Liabilities and Shareholders Equity stood at $87.4 million in 2021, then dropped by 15.16% to $74.2 million in 2022, then declined by 10.63% to $66.3 million in 2023, then declined by 15.68% to $55.9 million in 2024, then slipped by 18.39% to $45.6 million in 2025.
• Business Quant data shows MNOV's Liabilities and Shareholders Equity at $45.6 million in Q4 2025, $47.6 million in Q3 2025, and $49.8 million in Q2 2025.